Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9866884 | 0.92 | OPRM1 (0.44) | DNM1TSHROPRM1ADH1BADH1C | |
| SCHEMBL28219926 | 0.90 | OPRM1 (0.42) | DNM1TSHROPRM1ADH1BADH1C | |
| SCHEMBL28270182 | 0.90 | OPRM1 (0.42) | DNM1TSHROPRM1ADH1BADH1C | |
| SCHEMBL28219919 | 0.90 | OPRM1 (0.42) | DNM1TSHROPRM1ADH1BADH1C | |
| SCHEMBL28270193 | 0.90 | OPRM1 (0.42) | DNM1TSHROPRM1ADH1BADH1C | |
| SCHEMBL28616974 | 0.90 | OPRM1 (0.42) | DNM1TSHROPRM1ADH1BADH1C | |
| SCHEMBL940976 | 0.90 | OPRM1 (0.42) | DNM1TSHROPRM1ADH1BADH1C | |
| SCHEMBL28279026 | 0.90 | OPRM1 (0.42) | DNM1TSHROPRM1ADH1BADH1C | |
| SCHEMBL20605268 | 0.90 | TSHR (0.38) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 | |
| SCHEMBL7698918 | 0.87 | DNM1 (0.40) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633358-B2 | T-type calcium channel inhibitor | KINKI UNIVERSITY (JP) | 2020-04-28 | — | — | US | disclosed |
| CN-106893581-B | Organic electroluminescent compounds, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2019-11-05 | — | — | CN | disclosed |
| CN-106892915-B | Organic compound, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-106892914-B | Organic electroluminescent compounds, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2019-02-01 | — | — | CN | disclosed |
| CN-106588946-B | 10-hydroxycamptothecine derivative, synthetic method and its application | 郑州大学 | 2019-01-22 | — | — | CN | disclosed |
| CN-105755480-B | Efficient acidic cleaner | 江苏筑磊电子科技有限公司 | 2018-06-19 | — | — | CN | disclosed |
| CN-108101922-A | Organic electroluminescent compounds, organic electroluminescence device and its application | 南京高光半导体材料有限公司 | 2018-06-01 | — | — | CN | disclosed |
| US-20180065947-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | UNIV KINKI (JP) | 2018-03-08 | — | — | US | disclosed |
| US-20160096815-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | KINKI UNIVERSITY (JP) | 2016-04-07 | — | — | US | disclosed |
| EP-3000465-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | Kinki University (JP) | 2016-03-30 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| CN-1957057-A | Novel working substance pair for absorption heat pump, absorption refrigerator and heat converter | BASF AG (DE) | 2007-05-02 | — | — | CN | disclosed |
| US-6995163-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-6951865-B2 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI CO., LTD. (JP) | 2005-10-04 | — | — | US | disclosed |
| US-6927221-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| EP-1408040-A1 | Tricyclic fused heterocyclic compounds as CRFantagonists | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1238979-A1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096815-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1G, CACNA1H, CACNA1I | DNM1 736/4885TSHR 1147/4885SMN1; SMN2 3065/4885 |
| US-20180065947-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1G, CACNA1H, CACNA1I | DNM1 750/4885TSHR 1227/4885SMN1; SMN2 3194/4885 |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | NR3C2, CRHR1, CRHR2 | DNM1 2148/4885TSHR 140/4885SMN1; SMN2 3994/4885 |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | DNM1 3757/4885TSHR 47/4885SMN1; SMN2 3935/4885 |
| US-10633358-B2 | T-type calcium channel inhibitor | CACNA1G, CACNA1H, CACNA1I | DNM1 750/4885TSHR 1227/4885SMN1; SMN2 3194/4885 |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | DNM1 3757/4885TSHR 47/4885SMN1; SMN2 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.